Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Regeneron Pharmaceuticals (REGN)

Regeneron Pharmaceuticals (REGN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 32,970,168
  • Shares Outstanding, K 109,831
  • Annual Sales, $ 6,711 M
  • Annual Income, $ 2,444 M
  • 60-Month Beta 1.14
  • Price/Sales 4.94
  • Price/Cash Flow 13.58
  • Price/Book 3.39

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 19 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/19
See More
  • Average Estimate 5.13
  • Number of Estimates 1
  • High Estimate 5.13
  • Low Estimate 5.13
  • Prior Year 5.10
  • Growth Rate Est. (year over year) +0.59%

Price Performance

See More
Period Period Low Period High Performance
1-Month
271.37 +10.62%
on 09/27/19
310.15 -3.21%
on 10/14/19
+15.13 (+5.31%)
since 09/18/19
3-Month
271.37 +10.62%
on 09/27/19
314.95 -4.69%
on 07/29/19
-2.90 (-0.96%)
since 07/18/19
52-Week
271.37 +10.62%
on 09/27/19
442.00 -32.08%
on 03/04/19
-95.03 (-24.04%)
since 10/18/18

Most Recent Stories

More News
Regeneron Announces Upcoming Investor Conference Presentations

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management presentations as follows:

REGN : 300.19 (-0.46%)
Global Ophthalmic Drugs Market, Current Trends, Competitive Landscape and Forecasts till 2022

The Global Ophthalmic Drugs Market was valued at US$ XX Mn in 2016 and is expected to reach US$ XX Mn by 2022 growing at a CAGR of XX% during the forecast period . As seen, the ophthalmic industry is a...

BAYRY : 18.1900 (-0.49%)
PFE : 36.46 (unch)
REGN : 300.19 (-0.46%)
VRX.TO : 30.80 (-3.33%)
Alexion Pharm has the Best Relative Performance in the Biotechnology Industry (ALXN , INCY , REGN , AMGN , BIIB )

Below are the top five companies in the Biotechnology industry as measured by relative performance. This analysis was compiled based on yesterday's trading activity as we search for stocks that have the...

ALXN : 98.41 (-1.58%)
INCY : 77.76 (+0.43%)
REGN : 300.19 (-0.46%)
Regeneron Pharm Set to Possibly Pullback After Yesterday's Rally of 2.55%

Regeneron Pharm (NASDAQ:REGN) traded in a range yesterday that spanned from a low of $298.90 to a high of $305.98. Yesterday, the shares gained 2.6%, which took the trading range above the 3-day high...

REGN : 300.19 (-0.46%)
Wet AMD Space in Focus: New Drug Approvals & Key Advancements

The FDA approval of Novartis' Beovu for wet AMD brings this space to focus. Let us assess the recent key developments in the area.

RHHBY : 36.8100 (+0.68%)
BAYRY : 18.1900 (-0.49%)
AGN : 173.60 (+0.64%)
NVS : 86.88 (-0.40%)
REGN : 300.19 (-0.46%)
RGNX : 37.75 (-3.28%)
Dermira Starts Lebrikizumab Dosing in Late-Stage Eczema Study

Dermira (DERM) starts a phase III program for evaluation of its monoclonal antibody candidate, lebrikizumab, in adolescents and adult patients with atopic dermatitis, the most common form of eczema.

LLY : 108.64 (+0.17%)
SNY : 46.17 (-0.71%)
REGN : 300.19 (-0.46%)
DERM : 7.16 (+25.83%)
Regeneron to Report Third Quarter 2019 Financial and Operating Results and Host Conference Call and Webcast on November 5, 2019

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its third quarter 2019 financial and operating results on Tuesday, November 5, 2019, before the U.S. financial markets...

REGN : 300.19 (-0.46%)
Novartis' (NVS) Wet AMD Drug Beovu Obtains FDA Approval

Novartis (NVS) wins FDA approval for Beovu injection for the treatment of wet AMD at a three-month dosing interval.

NVS : 86.88 (-0.40%)
RHHBY : 36.8100 (+0.68%)
BAYRY : 18.1900 (-0.49%)
REGN : 300.19 (-0.46%)
Look for Shares of Regeneron Pharm to Potentially Pullback after Yesterday's 1.15% Rise

Regeneron Pharm (NASDAQ:REGN) traded in a range yesterday that spanned from a low of $280.66 to a high of $287.77. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high...

REGN : 300.19 (-0.46%)
Regeneron Pharm Down 5.2% Since SmarTrend Downtrend Call (REGN)

SmarTrend identified a Downtrend for Regeneron Pharm (NASDAQ:REGN) on July 11th, 2019 at $292.50. In approximately 3 months, Regeneron Pharm has returned 5.16% as of today's recent price of $277.40.

REGN : 300.19 (-0.46%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Average.

See More Share

Trade REGN with:

Business Summary

Regeneron Pharmaceuticals Inc. is a biopharmaceutical company that discovers, develops, and intends to commercialize therapeutic medicines for the treatment of serious medical conditions. Regeneron has therapeutic candidates for the potential treatment of obesity, rheumatoid arthritis, cancer, and asthma...

See More

Key Turning Points

2nd Resistance Point 305.61
1st Resistance Point 302.90
Last Price 300.19
1st Support Level 298.09
2nd Support Level 295.99

See More

52-Week High 442.00
Fibonacci 61.8% 376.82
Fibonacci 50% 356.68
Fibonacci 38.2% 336.55
Last Price 300.19
52-Week Low 271.37

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar